Helmholtz Association

A diabetes drug for Alzheimer's

From research conducted at the German Centre for Neurodegenerative Diseases (DZNE)
Photo Dr. Krauß

Dr. Sybille Krauß performing cell culture experiments in the lab. Photo/Graphic: DZNE.Read more

The diabetes drug metformin may be suitable for treating Alzheimer’s disease – this is one of the conclusions that researchers under Dr. Sybille Krauß at the DZNE laboratory in Bonn have drawn from the findings of their experiments.

In patients with Alzheimer’s disease, the tau protein changes its structure, forming deposits in the brain. This process is thought to contribute to the death of nerve cells. The researchers have shown that metformin counteracts the structural changes in tau. Hence, the drug could potentially prevent the formation of abnormal protein deposits and the death of brain cells. The team also shed light on the molecular mechanism by which metformin acts. If additional experiments on Alzheimer’s mice proceed positively, clinical studies could begin shortly.

Joachim Czichos

Media about the subject

Links

DZNE



11.06.2013

Contact

Dr. Phillip Hahn

Research Field Health

Helmholtz Association

Phone: +49 30 206329-15
phillip.hahn (at) helmholtz.de


Communications and Media

Helmholtz Association

Phone: +49 30 206329-57
presse (at) helmholtz.de